Galectin Therapeutics Net Tangible Assets

Galectin Therapeutics (GALT) currently reports a net tangible assets of $-140M as of June 2026. That compares with $-120M in the prior-year period — down 16.8% year over year. Use the charts on this page to explore Galectin Therapeutics's net tangible assets history and peer comparisons.

Galectin Therapeutics's net tangible assets decreased from $-120M to $-140M — a 16.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Galectin Therapeutics reported $-140M in net tangible assets as of June 2026. That compares with $-120M in the prior-year period — down 16.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $-140M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Galectin Therapeutics, and consider following GALT for alerts when major investors trade the stock.

Galectin Therapeutics is classified in the Healthcare sector. On net tangible assets, it currently shows $-140M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GALT with unrelated industries.